ArticleAnimal bioscience2026
Alleviating calf weaning stress: the important role of maternal bovine appeasing substance in calf husbandry management.
Article in Animal bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveWeaning stress impairs calf health by causing growth retardation and immune dysfunction, underscoring the need for targeted interventions. Maternal bovine appeasing substance (MBAS) has been proposed as a novel therapy for stress in cattle, but its efficacy against weaning stress remains unclear. This study assessed the health impacts of weaning and evaluated MBAS as a potential intervention.
methodsHealth impacts were first evaluated in 60 weaned Holstein calves. Then, another 60 healthy calves of similar age were randomly divided into two groups (n = 30/group). Control calves received a single 2.5 mL saline spray one day pre-weaning, while the MBAS group received a single 2.5 mL spray of MBAS (100 mg/mL).
resultsWeaning stress increased diarrhea (56.52% to 78.26%) and respiratory disease incidence (10.17% to 15.88%), elevated exercise steps (32,196±1,267 vs 38,226±1,132, p = 0.0043), and reduced dry matter intake (2.78±0.03 vs 2.59±0.06 kg/d at D4, p = 0.0041) and average daily gain (ADG, 0.89±0.05 vs 0.71±0.04 kg/d, p = 0.0230) within 15 days post-weaning. MBAS improved ADG (0.92±0.15 vs 1.25±0.14 kg/d at D7, p = 0.0120), lowered respiratory disease (23.07% to 17.42%) and diarrhea incidence (83.70% to 52.70%), and shortened diarrhea duration (4.32±0.47 d vs 3.15±0.32 d, p = 0.0090). It also reduced serum interleukin-1 (49.39±2.40 vs 43.51±1.64 pg/mL, p = 0.0350), haptoglobin (58.29±3.3 vs 49.40±3.65 μg/mL, p = 0.0050), and cortisol (37.42±1.67 vs 33.05±2.24 nmol/L, p = 0.0310), while increasing immunoglobulin G (10.30±1.46 vs 13.50±1.58 μg/mL, p = 0.0131) and interferon-γ (6.89±0.47 vs 7.94±0.63 ng/L, p = 0.0330) on D5.
conclusionMBAS alleviates weaning stress by inhibiting inflammation, enhancing immunity, and reducing anxiety, providing an effective strategy to improve calf health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.